Pioglitazone

Česká verzia

Authors: David Karásek
Authors place of work: III. Interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
Published in the journal: Vnitř Lék 2020; 66(2): 121-125
Category:

Summary

Pioglitazone belongs to the drugs primarily reducing insulin resistance. Currently, it is the only insulin sensitizer available. In addition to hypoglycaemic action, it has a number of other metabolically beneficial effects that are responsible for its positive effect on the vascular wall. The paper provides an overview of cardiovascular clinical trials with pioglitazone, its safety profile and practical recommendations for its administration.

Keywords:

diabetes – pioglitazone – insulin resistance – heart failure – cardiovascular disease – Bladder cancer

Zdroje

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‑analysis of 102 prospective studies. Lancet 2010; 375: 2215–2222.

2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.

3. DeFronzo RA, Inzucchi S, Abdul‑Ghani M, Nissen SE. Pioglitazone: The forgotten, cost‑effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 2019; 16: 133–143.

4. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547–1554.

5. Deeg MA, Buse JB, Goldberg RB, et al.; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458–2464.

6. Zou C, Hu H. Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag 2013; 9: 429–433.

7. Sourij H, Wascher TC. Pioglitazone in the management of Type 2 diabetes and beyond. Therapy 2007; 4: 517–533.

8. Alam F, Islam MA, Mohamed M, et al. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta‑Analysis of Randomised Controlled Trials. Sci Rep 2019; 9: 5389.

9. Tan MH, Baksi A, Krahulec B, et al.; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28: 544–550.

10. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima‑media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572–2581.

11. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452–3456.

12. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561–1573.

13. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of athe‑ rosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393–399.

14. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29: 101–106.

15. Patel D, Walitt B, Lindsay J, Wilensky RL. Role of pioglitazone in the prevention of restenosis and need for revascularization after bare‑metal stent implantation: a meta‑analysis. J Am Coll Cardiol Intv 2011; 4: 353–360.

16. Althouse AD, Abbott JD, Sutton‑Tyrrell K, et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2013; 36: 3269–3275.

17. Dormandy JA, Betteridge DJ, Schernthaner G, et al. PROactive investigators. Impact of peripheral arterial disease in patients with diabetes — results from PROactive (PROactive 11). Atherosclerosis 2009; 202: 272–281.

18. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289.

19. Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865–873.

20. Kernan WN, Viscoli CM, Furie KL, et al. IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374: 1321–1331.

21. De Jong M, Vander Worp HB, Vander Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta‑analysis of randomized‑controlled trials. Cardiovasc Diabetol 2017; 16: 134.

22. Vaccaro O, Masulli M, Nicolucci A, et al. Effects on their incidence of cardiovascular events of the addition of pioglitazonem versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887–897.

23. Abdul‑Ghani M, Jayyous A, Asaad N, et al. Pioglitazone and cardiovascular risk in T2DM patients: is it good for all? Ann Transl Med 2018; 6:192.

24. Strongman H, Christopher S, Majak M, et al. Pioglitazone and cause‑specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care 2018; 6: e000481.

25. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second‑line, glucose‑lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 4605–4612.

26. Morgan CL, Inzucchi SE, Puelles J, et al. Impact of treatment with pioglitazone on stro‑ ke outcomes: A real‑world database analysis. Diabetes Obes Metab 2018; 20: 2140–2147.

27. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017; 19:1353–1362.

28. Karásek D. Vliv antidiabetické léčby na kost nemocných s DM 2. typu. Vnitř Lék 2016; 62: 582–587.

29. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 2015; 314: 265–277.

30. Erdmann E, Harding S, Lam H, et al. Ten‑year observational follow‑up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 2016; 18: 266–273.

31. Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the Risk of Bladder Cancer: A Meta‑Analysis. Diabetes Ther 2017; 8: 705–726.

32. Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four Eu‑ ropean countries. BMJ 2016; 354: i3903.

33. Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta‑analysis. Cancer Med 2018; 7: 1070–1080.

34. Adil M, Khan RA, Ghosh P, et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta‑analysis of observational studies using real‑world data. Clin Epidemiol Glob Health 2018; 6: 61–68.

35. Qu H, Zheng Y, Wang Y, et al. Global and Regional Effects of Bladder Cancer Risk Asso‑ ciated with Pioglitazone Therapy in Patients with Diabetes. Sci Rep 2017; 7: 15804.

36. https://www.ema.europa.eu/en/documents/product‑information/pioglitazone‑accord‑epar‑product‑information_cs.pdf

37. Pelikánová T, Bartoš V, a kol. Praktická diabetologie, 6. aktualizované a doplněné vydání. Praha: Maxdorf 2018.

38. Chou PS, Ho BL, Yang YH. Effects of pioglitazone on the incidence of dementia in patients with diabetes. J Diabetes Complications 2017; 31: 1053–1057.

39. Tseng CH. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis. J Clin Med 2018; 7: 306.

40. Bailey CJ, Feher MD. Therapies for Diabetes: Including Oral Agents and Insulins. Birmingham UK: Sherborne Gibbs Limited 2004.